Klotho

Klotho usually refers to alpha-klotho, an endogenous transmembrane and soluble protein involved in phosphate handling, FGF23 signaling, vitamin D metabolism, kidney biology, and aging-related pathways. The evidence base is scientifically rich but therapeutically immature. Mouse genetics established that klotho deficiency produces premature-aging-like phenotypes, while klotho overexpression or soluble klotho strategies have been associated with lifespan, tissue, kidney, or cognitive effects in animal models. Human evidence is mostly observational, especially in chronic kidney disease where soluble klotho tends to decline while FGF23 rises as mineral metabolism becomes disrupted. No FDA-approved recombinant klotho therapy exists for longevity, cognition, kidney disease, or metabolic use.

Kidney-Mineral Biology

Klotho is central to FGF23-mediated phosphate and vitamin D regulation, making it important in kidney-mineral metabolism research ^[1][2].

Aging and Cognition Models

Mouse overexpression studies reported lifespan extension, and aged nonhuman primates given low-dose klotho showed improved memory performance ^[3][5].

Human Observational Context

CKD studies associate reduced soluble klotho with kidney disease progression and altered FGF23/mineral metabolism, but association is not treatment proof ^[2][4].

Not an Approved Human Drug

Klotho is not an approved human drug; longevity, cognition, and kidney-protection claims remain investigational ^[1][5].

Mineral Metabolism Risk

Because klotho participates in FGF23, phosphate, calcium, and vitamin D regulation, exogenous manipulation could plausibly disturb mineral metabolism ^[1][2].